HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
1- (2- nitro- 1- imidazolyl)- 3- aziridino- 2- propanol
structure given in first source
Also Known As:
NSC 347503; NSC-347503; RSU 1069; RSU-1069; 1H-Imidazole-1-ethanol, alpha-(1-aziridinylmethyl)-2-nitro-
Networked:
39
relevant articles (
1
outcomes,
7
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Nitro Compounds: 66
Nitroimidazoles: 565
Misonidazole: 539
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol: 39
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
Nitroimidazoles: 565
Misonidazole: 539
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol: 39
Experts
1.
Banáth, Judit P
: 1 article (08/2002)
2.
Durand, Ralph E
: 1 article (08/2002)
3.
Olive, Peggy L
: 1 article (08/2002)
Related Diseases
1.
Hypoxia (Hypoxemia)
09/01/1987 - "
In spheroids, hypoxia-induced toxicity after aerobic exposure decreased as the time between RSU 1069 exposure and hypoxic incubation increased; spheroid cells exposed to RSU 1069 under air lost sensitivity to subsequent hypoxic incubation with a half-time of about 10 hr, representing the time for cell turnover and/or repair from damage produced under aerobic conditions.
"
11/01/1989 - "
Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
"
03/01/1997 - "
Results using the hypoxic cell cytotoxin RSU 1069 confirmed that the extent of hypoxia was not as severe in the testis as in the SCCVII murine tumour.
"
01/01/1992 - "
The dose enhancement ratios for SR 4233 and RSU 1069 were 8.8 and 8.5, respectively, showing that these agents had an equivalent and substantial enhancement of their cytotoxicity when combined with hypobaric hypoxia.
"
04/01/1989 - "
The ability of cellular systems to repair damage induced by RSU-1069 may play a significant role in determining its efficiency to act as a hypoxic cell radiosensitizer and a hypoxia selective cytotoxin.
"
2.
Neoplasms (Cancer)
07/01/1986 - "
For toxicity studies, tumors were excised 16-18 hr after RSU-1069 administration.
"
09/01/1987 - "
Results using V79 spheroids similarly suggest that tumor excision soon after injection of RSU 1069 can give false information on RSU 1069 toxicity if efforts are not made to prevent tumor hypoxia during processing.
"
09/01/1987 - "
Cytotoxicity of RSU 1069 in spheroids and murine tumors.
"
07/01/1986 - "
The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
"
07/01/1986 - "
Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios.
"
3.
Sarcoma (Soft Tissue Sarcoma)
12/01/1985 - "
The present studies evaluated the therapeutic benefit of combining RSU 1069 and CCNU in KHT sarcoma-bearing C3H/HeJ mice.
"
07/01/1991 - "
For RSU 1069 and RB 6145, administered by either route, the maximum hypoxic cell radiosensitization in murine KHT sarcomas, occurred when the drugs were given 45-60 min before 10 Gy of X rays.
"
04/01/1989 - "
RSU-1069 is a highly effective hypoxic cell cytotoxin in KHT sarcomas treated in vivo.
"
09/01/1984 - "
These results indicate that potentiation of melphalan activity occurs at RSU 1069 doses which are approximately 10-fold lower than those of MISO, making this sensitizer as effective a potentiator of melphalan as so far tested in the KHT sarcoma.
"
09/01/1984 - "
Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
"
4.
Carcinoma (Carcinomatosis)
08/01/2002 - "
In an effort to estimate the extent and range of oxygenation in SiHa human cervical carcinoma xenografts, patterns of cell killing and DNA damage by radiation and two bioreductive drugs, PD-144872 and RSU-1069, were compared to those seen in SiHa cells grown as spheroids.
"
01/01/1988 - "
The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.
"
05/01/1993 - "
Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069.
"
12/15/1997 - "
Chinese hamster V79 cells, SiHa human cervical carcinoma cells, and WiDr human colon carcinoma cells were grown as spheroids and exposed to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), 4-nitroquinoline-1-oxide (4NQO), doxorubicin, etoposide, actinomycin D, 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol (RSU 1069), 3-amino-1,2,4-benzotriazine-1,4-dioxide (tirapazamine), and nitrogen mustard.
"
5.
Hyperthermia
08/01/1991 - "
Effect of oxygenation, pH and hyperthermia on RSU-1069 in vitro and in vivo with radiation in the FSaIIC murine fibrosarcoma.
"
08/01/1991 - "
Hoechst 33342 diffusion selected FSaIIC tumor subpopulation studies revealed that hyperthermia and RSU-1069 were more toxic towards dim (hypoxic) cells, while radiation was more toxic towards bright (normally oxygenated) cells.
"
08/01/1991 - "
We have evaluated the combination of the radiosensitizing and bioreductive alkylating agent RSU-1069 with hyperthermia and radiation in an attempt to improve the potential effectiveness of hyperthermia and radiation against locally advanced malignancies.
"
01/01/1988 - "
The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.
"
Related Drugs and Biologics
1.
Misonidazole
2.
Hydralazine (Apresoline)
3.
Vasodilator Agents (Vasodilators)
4.
Cytotoxins (Cytolysins)
5.
Tirapazamine (SR 4233)
6.
Doxorubicin (Adriamycin)
7.
Cytostatic Agents
8.
Lomustine (CCNU)
9.
Fluorouracil (Carac)
10.
Carmustine (FIVB)
Related Therapies and Procedures
1.
Therapeutics
2.
Microspheres (Microsphere)
3.
Intraperitoneal Injections